A Phase 1 Clinical Trial of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer.

Inclusion Criteria:

- Patients must be male and at least 18 years of age at the time of signing the informed
consent.

- Patients must present with histological, pathological, or cytological confirmed
diagnosis of advanced or metastatic castration resistant adenocarcinoma of the
prostate.

- Patients must have progressed on at least 2 prior approved systemic therapies for CRPC
(at least one must be abiraterone or enzalutamide).

- Patients with progressive mCRPC

- Patients must have ongoing ADT with a gonadotropin releasing hormone analog or
inhibitor, or orchiectomy (surgical or medical castration).

Exclusion Criteria:

- Patients with known symptomatic brain metastases requiring steroids (above physiologic
replacement doses)

- Major surgery (as defined by the Investigator) within 4 weeks of first dose of study
drug.

- Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to
>25% of the bone marrow. Palliative radiation for the alleviation of pain due to bone
metastasis will be allowed during the study

- Systemic anti cancer therapy within 2 weeks of first dose of study drug (6 weeks for
bicalutamide, mitomycin C, or nitrosoureas and 4 weeks for abiraterone). Patients are
ineligible if they received any other type of anti cancer agent (except agents to
maintain castrate status) within 2 weeks before first dose of study drug.